Clinical trials: Adolescent Depression
Depression
Adapting Behavioral Activation to Technology Platform
This project aims to use an asynchronous remote communities (ARC) approach both to discover the design requirements for adapting Behavioral Activation (BA) to ARC as well as design/build an ARC platform for administering BA.
- Trial name
- NCT03783533
- Testing
- Behavioral Activation
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Washington
Major Depressive Disorder
Safety and Effectiveness of NeuroStar® Transcranial Magnetic Stimulation (TMS) Therapy in Depressed Adolescents
To evaluate the safety and efficacy of daily, active Neurostar® TMS (when compared with sham treatment) in adolescents meeting criteria for Major Depressive Disorder (MDD).
- Trial name
- NCT02586688
- Testing
- Active NeuroStar® Transcranial Magnetic Stimulation (TMS)
- Where
- 13 sites in United States
- Volunteers
- 112 people
- Sponsor
- Neuronetics
Psychological Stress, Depression
Boricua Youth Study COVID-19 Coping Intervention Study
The current study is the second phase of a two-part study to examine the feasibility and utility of using an mHealth mindfulness intervention to help parents mitigate the stress associated with the impact of sustained community…
- Conditions
- Psychological Stress, Depression, Anxiety
- Trial name
- NCT05444881
- Testing
- Mindfulness-based Intervention (Headspace TM)
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- New York State Psychiatric Institute
Depressive Disorder
A Study of Duloxetine (LY248686) in Japanese Children and Adolescents With Depressive Disorder
The purpose of this study is to determine the efficacy of duloxetine hydrochloride versus placebo in the treatment of Japanese children and adolescents with depressive disorder.
- Trial name
- NCT03315793
- Testing
- Duloxetine Hydrochloride
- Where
- Japan
- Volunteers
- 149 people
- Sponsor
- Shionogi
Adolescent Depression
An Adaptive Treatment Strategy for Adolescent Depression-Continuation
Aim 1: Assess the feasibility and acceptability of the personalized continuation treatment strategy. Aim 2: Estimate variances of primary and secondary outcomes with the continuation treatment.
- Trial name
- PTAD GIA (NCT02017535)
- Testing
- Fluoxetine, Interpersonal Psychotherapy
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Minnesota
Adolescent Depression
Omega-3 Fatty Acids in Adolescent Depression
Aim. To provide preliminary data about the efficacy of omega-3FA in the treatment of adolescent MDD. To address this aim, a 10-week double blind, placebo-controlled study of omega-3FA, using a flexible dose titration is proposed.
- Trial name
- NCT00312897
- Testing
- Omega-3 Fatty Acids, corn oil
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Depression, Major Depressive Disorder
Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) In The Treatment Of Child And Adolescent Outpatients With Major Depressive Disorder
The primary purpose of this study is to test the safety and tolerability of single ascending doses of Desvenlafaxine Succinate Sustained-Release (DVS SR) in both child and adolescent outpatients with major depressive disorder.
- Trial name
- NCT00619619
- Testing
- Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR)
- Where
- 9 sites in United States
- Volunteers
- 59 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Major Depressive Disorder
A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD
This is a double-blind study evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) versus placebo in the Treatment of Children and Adolescent Outpatients with Major Depressive Disorder (MDD).
- Trial name
- NCT01371734
- Testing
- Desvenlafaxine Succinate Sustained-Release
- Where
- 42 sites in United States, Chile and 1 more
- Volunteers
- 363 people
- Sponsor
- Pfizer
Major Depressive Disorder
A Study in the Treatment of Children and Adolescents With Major Depressive Disorder
The purpose of this study is to assess whether duloxetine is superior to placebo in the treatment of children and adolescents with major depressive disorder (MDD)
- Trial name
- NCT00849693
- Testing
- fluoxetine, duloxetine
- Where
- 56 sites in United States, Argentina and 2 more
- Volunteers
- 463 people
- Sponsor
- Eli Lilly and Company
Depressive Disorder
Paxil Japanese Post Marketing Paediatric Study in Depression (Double-blind, Placebo Controlled Study)
This study is designed to compare the efficacy of oral paroxetine 10 to 40 mg/day (initial dose:10 mg/day) versus placebo administered once daily (after evening meal) for 8 weeks in children and adolescents with major depressive…
- Trial name
- NCT00812812
- Testing
- paroxetine 10mg tablet, paroxetine 20mg tablet
- Where
- 33 sites in Japan
- Volunteers
- 56 people
- Sponsor
- GlaxoSmithKline
Major Depressive Disorder
Phase IV:Safety and Efficacy of EMSAM in Adolescents With Major Depression
The primary purpose of your participation in this study is to help answer the following research question: Whether 12-week administration of EMSAM (selegiline transdermal system) is safe and effective for the treatment of…
- Trial name
- NCT00531947
- Testing
- Selegiline Transdermal System
- Where
- 20 sites in United States
- Volunteers
- 308 people
- Sponsor
- Somerset Pharmaceuticals